Medexus Pharmaceuticals (MDP.T), a Canadian-based specialty pharma company focused on acquiring and distributing innovative rate disease treatment solutions, announced its financial results for Q1 2023. The company reported a…
Rupall
Medexus Pharmaceuticals (MDP.V) announced that they’re making their Triamcinolone Hexacetonide (TH) Injectable Suspension, USP (20 mg/ml) available in the United States through the FDA’s CDER Drug Shortage program in…